Floatz logo

Hynr-Cs-Allo

Neurodegenerative Disease

Hanyang University Seoul HospitalCell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Neurodegenerative Disease cohort.

Asset / SponsorPhaseRating
Nexiguran Ziclumeran
Intellia Therapeutics
Phase 3B
Dextromethorphan
National Institute of Neurological Disorders and Stroke (NINDS)
Phase 2B

Same molecule, other indications

Hynr-Cs-Allo is also rated in:

neuromuscular diseaseDormant
CC
Indicative ·
47 / 100
View asset →
central nervous system disorderDormant
CC
Indicative ·
47 / 100
View asset →
Motor Neuron DiseaseDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →